Brief: aTyr Pharma Reports FDA Orphan Drug Designation for Efzofitimod for Treatment of Systemic Sclerosis
13/04/2022 13:34
April 13 (Reuters) - aTyr Pharma Inc LIFE.O :
* ATYR PHARMA ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR
EFZOFITIMOD (ATYR1923) FOR TREATMENT OF SYSTEMIC SCLEROSIS
Source text for Eikon: ID:nGNX358YvT
Further company coverage: LIFE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan